关键词： BNCT BPA BSH Design of clinical trials Glioblastoma

Mesh ： Adult Aged Antineoplastic Agents, Alkylating / therapeutic use Borohydrides / therapeutic use Boron Compounds / therapeutic use Boron Neutron Capture Therapy / mortality Brain Neoplasms / diagnosis mortality therapy Chemoradiotherapy / mortality Dacarbazine / analogs & derivatives therapeutic use Female Germany / epidemiology Glioblastoma / diagnosis mortality therapy Humans Male Middle Aged Phenylalanine / analogs & derivatives therapeutic use Prevalence Risk Factors Survival Rate Temozolomide Treatment Outcome

来  源：   DOI：10.1016/j.apradiso.2013.11.092   PDF(Sci-hub)

Abstract：
Boron neutron capture therapy (BNCT) with Na2B12H11SH (BSH) or p-dihydroxyborylphenylalanine (BPA), and with a combination of both, was compared to radiotherapy with temozolomide, and the number of patients required to show statistically significant differences between the treatments was calculated. Whereas arms using BPA require excessive number of patients in each arm, a two-armed clinical trial with BSH and radiotherapy plus temozolomide is feasible.
摘要：
用Na2B12H11SH（BSH）或对二羟基硼基苯丙氨酸（BPA）进行硼中子俘获治疗（BNCT），两者的结合，与替莫唑胺的放射治疗相比，并计算显示两种治疗之间有统计学意义差异所需的患者人数。而使用BPA的手臂需要每个手臂的患者数量过多，BSH和放疗加替莫唑胺的双臂临床试验是可行的.
公众号